{"entity":{"id":"robert-coleman","kind":"person","name":"Robert L. Coleman","aka":[],"tldr":"Gynaecologic oncologist who led ARIEL3 and GOG-0213, shaping PARP maintenance and secondary surgery in relapsed ovarian cancer.","summary":"Robert Coleman (US Oncology Research, Texas) was principal investigator of ARIEL3, which established rucaparib maintenance in recurrent ovarian cancer, and of GOG-0213, which found no survival benefit from secondary cytoreductive surgery but confirmed bevacizumab's benefit at relapse. He served as GOG programme director and has led many NRG gynaecological trials.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Coleman%20RL%5BAuthor%5D%20ovarian%20rucaparib"}],"tags":["ovarian","parp","surgery"],"related":[],"cancers":["ovarian"],"sections":[],"technologies":["parp-inhibitor","antiangiogenic"],"targets":["parp","vegf"],"drugs":[],"companies":[],"institutions":["us-oncology-network"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Chief Scientific Officer, US Oncology Research; Gynecologic Oncologist, Texas Oncology","institutionId":"us-oncology-network","specialisms":["Ovarian cancer","PARP inhibitors","Antiangiogenic therapy","Surgical trials"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Coleman%20RL%5BAuthor%5D%20ovarian%20rucaparib"}],"papers":[{"title":"Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3)","journal":"Lancet","year":2017,"doi":"10.1016/S0140-6736(17)32440-6"},{"title":"Secondary surgical cytoreduction for recurrent ovarian cancer (GOG-0213)","journal":"NEJM","year":2019,"doi":"10.1056/NEJMoa1902626"}]},"route":"/people/robert-coleman/","neighbours":{"cancer":[{"id":"ovarian","kind":"cancer","name":"Ovarian cancer","route":"/cancers/ovarian/"}],"technology":[{"id":"antiangiogenic","kind":"technology","name":"Anti-angiogenic therapy","route":"/technologies/antiangiogenic/"},{"id":"parp-inhibitor","kind":"technology","name":"PARP inhibitors","route":"/technologies/parp-inhibitor/"}],"target":[{"id":"parp","kind":"target","name":"PARP","route":"/targets/parp/"},{"id":"vegf","kind":"target","name":"VEGF / VEGFR","route":"/targets/vegf/"}],"institution":[{"id":"us-oncology-network","kind":"institution","name":"The US Oncology Network / US Oncology Research","route":"/institutions/us-oncology-network/"}]}}